Semi-national surveillance of fungaemia in Denmark 2004-2006: Increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility

Clinical Microbiology and Infection

Volumn 14, Issue 5, 2008, Pages 487-494

  Arendrup, M C ^a   Fuursted, K ^b   Gahrn Hansen, B ^c   Schonheyder H C ^d   Knudsen, J D ^e   Jensen, I M ^f   Bruun, B ^g   Christensen, J J ^h   Johansen, H K ⁱ  

^a STATENS SERUM INSTITUT   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d AALBORG UNIVERSITY HOSPITAL   (Denmark)

^e HVIDOVRE HOSPITAL   (Denmark)

^f GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^g HILLERØD HOSPITAL   (Denmark)

^h Mental Health Services CPH   (Denmark)

ⁱ Rigshospitalet   (Denmark)

Author keywords

Candida spp; Denmark; Fluconazole; Fungaemia; Resitance; Surveillance

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; PYRROLE; VORICONAZOLE;

ADULT; AGED; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CONTROLLED STUDY; DENMARK; FEMALE; FUNGAL VIRULENCE; FUNGEMIA; FUNGUS ISOLATION; HEALTH SURVEY; HUMAN; INCIDENCE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SPECIES IDENTIFICATION; UNIVERSITY HOSPITAL;

CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; ISSATCHENKIA ORIENTALIS;

EID: 41949093350     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2008.01954.x     Document Type: Article

References (29)

1. Arendrup MC, Fuursted K, Gahrn-Hansen B et al. Seminational surveillance of fungemia in Denmark: Notably high rates of fungemia and numbers of isolates with reduced azole susceptibility. J Clin Microbiol 2005; 43: 4434-4440.
2. Sandven P, Bevanger L, Digranes A, Haukland HH, Mannsaker T, Gaustad P. Candidemia in Norway (1991 to 2003): Results from a nationwide study. J Clin Microbiol 2006; 44: 1977-1981.
3. Klingspor L, Tornqvist E, Johansson A, Petrini B, Forsum U, Hedin G. A prospective epidemiological survey of candidaemia in Sweden. Scand J Infect Dis 2004; 36: 52-55.
4. Poikonen E, Lyytikainen O, Anttila VJ, Ruutu P. Candidemia in Finland, 1995-1999. Emerg Infect Dis 2003; 9: 985-990.
5. Tortorano AM, Kibbler C, Peman J, Bernhardt H, Klingspor L, Grillot R. Candidaemia in Europe: Epidemiology and resistance. Int J Antimicrob Agents 2006; 27: 359-366.
6. Peman J, Canton E, Gobernado M. Epidemiology and antifungal susceptibility of Candida species isolated from blood: Results of a 2-year multicentre study in Spain. Eur J Clin Microbiol Infect Dis 2005; 24: 23-30.
7. Almirante B, Rodriguez D, Park BJ et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: Results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2005; 43: 1829-1835.
8. Asmundsdottir LR, Erlendsdottir H, Gottfredsson M. Increasing incidence of candidemia: Results from a 20-year nationwide study in Iceland. J Clin Microbiol 2002; 40: 3489-3492.
9. Tortorano AM, Peman J, Bernhardt H et al. Epidemiology of candidaemia in Europe: Results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 2004; 23: 317-322.
10. Kao AS, Brandt ME, Pruitt WR et al. The epidemiology of candidemia in two United States cities: Results of a population-based active surveillance. Clin Infect Dis 1999; 29: 1164-1170.
11. Diekema DJ, Messer SA, Brueggemann AB et al. Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol 2002; 40: 1298-1302.
12. Hajjeh RA, Sofair AN, Harrison LH et al. Incidence of bloodstream infections due to Candida species and in.vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 2004; 42: 1519-1527.
13. Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. In.vitro susceptibilities of Candida spp. to caspofungin: Four years of global surveillance. J Clin Microbiol 2006; 44: 760-763.
14. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: A persistent public health problem. Clin Microbiol Rev 2007; 20: 133-163.
15. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Buitrago MJ, Monzon A, Rodriguez-Tudela JL. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother 2006; 50: 917-921.
16. Colombo AL, Nucci M, Salomao R et al. High rate of non- albicans candidemia in Brazilian tertiary care hospitals. Diagn Microbiol Infect Dis 1999; 34: 281-286.
17. Cuenca-Estrella M, Moore CB, Barchiesi F et al. Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). Clin Microbiol Infect 2003; 9: 467-474.
18. Cuenca-Estrella M, Arendrup MC, Chryssanthou E et al. Multicentre determination of quality control strains and quality control ranges for antifungal susceptibility testing of yeasts and filamentous fungi using the methods of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). Clin Microbiol Infect 2007; 13: 1018-1022.
19. The European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST). EUCAST Technical Note on fluconazole. Clin Microbiol Infect 2008; 14: 193-195.
20. Laupland KB, Gregson DB, Church DL, Ross T, Elsayed S. Invasive Candida species infections: A 5 year population-based assessment. J Antimicrob Chemother 2005; 56: 532-537.
21. Wenzel RP, Edmond MB. The impact of hospital-acquired bloodstream infections. Emerg Infect Dis 2001; 7: 174-177.
22. Sogaard M, Norgaard M, Schonheyder HC. First notification of positive blood cultures and the high accuracy of the gram stain report. J Clin Microbiol 2007; 45: 1113-1117.
23. Flaatten H. Epidemiology of sepsis in Norway in 1999. Crit Care 2004; 8: R180-R184.
24. Levy I, Rubin LG, Vasishtha S, Tucci V, Sood SK. Emergence of Candida parapsilosis as the predominant species causing candidemia in children. Clin Infect Dis 1998; 26: 1086-1088.
25. Pappas PG, Rex JH, Lee J et al. A prospective observational study of candidemia: Epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003; 37: 634-643.
26. Pfaller MA, Diekema DJ, Jones RN, Messer SA, Hollis RJ. Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J Clin Microbiol 2002; 40: 852-856.
27. Roilides E, Farmaki E, Evdoridou J et al. Neonatal candidiasis: Analysis of epidemiology, drug susceptibility, and molecular typing of causative isolates. Eur J Clin Microbiol Infect Dis 2004; 23: 745-750.
28. Sandven P, Bevanger L, Digranes A, Gaustad P, Haukland HH, Steinbakk M. Constant low rate of fungemia in Norway, 1991 to 1996. The Norwegian Yeast Study Group. J Clin Microbiol 1998; 36: 3455-3459.
29. Horvath LL, George BJ, Murray CK, Harrison LS, Hospenthal DR. Direct comparison of the BACTEC 9240 and BacT/ALERT 3D automated blood culture systems for candida growth detection. J Clin Microbiol 2004; 42: 115-118.